Insights

Strategic Partnerships Orphazyme A/S has engaged in strategic partnerships with companies like KemPharm, indicating potential collaboration opportunities for sales expansion through joint ventures or co-marketing initiatives.

Financial Growth Orphazyme's recent financial activities, such as the sale of assets to Zevra Therapeutics for $12.8M and strategic hires like Anders Vadsholt as CEO, suggest an upward growth trend that could signal opportunities for increased sales activities or investment partnerships.

Expanding Market Reach The expansion of Orphazyme's global presence with offices in Denmark, Switzerland, and the US, particularly their US headquarters in Chicago, offers a strong foothold for sales professionals to target untapped markets and engage with a diverse customer base.

Innovative Therapies Orphazyme's focus on pioneering innovative therapies for neurodegenerative orphan diseases presents unique selling opportunities for sales representatives to promote groundbreaking treatments and establish Orphazyme as a key player in the biotechnology sector.

Competitive Positioning In comparison to similar companies like iTeos Therapeutics, AlloVir, and MaaT Pharma, Orphazyme's positioning and funding of $109M provide a competitive edge for sales professionals to leverage in negotiations and demonstrate the company's strength in the market.

Orphazyme A/S Tech Stack

Orphazyme A/S uses 8 technology products and services including Modernizr, jQuery UI, IBM, and more. Explore Orphazyme A/S's tech stack below.

  • Modernizr
    Javascript Libraries
  • jQuery UI
    Javascript Libraries
  • IBM
    Miscellaneous
  • Ubuntu
    Operating Systems
  • WP Engine
    Platform As A Service
  • PHP
    Programming Languages
  • Yoast SEO
    Search Engines
  • Twitter
    Widgets

Media & News

Orphazyme A/S's Email Address Formats

Orphazyme A/S uses at least 1 format(s):
Orphazyme A/S Email FormatsExamplePercentage
First.Last@orphazyme.comJohn.Doe@orphazyme.com
45%
Last@orphazyme.comDoe@orphazyme.com
5%
First.Last@orphazyme.comJohn.Doe@orphazyme.com
45%
Last@orphazyme.comDoe@orphazyme.com
5%

Frequently Asked Questions

Where is Orphazyme A/S's headquarters located?

Minus sign iconPlus sign icon
Orphazyme A/S's main headquarters is located at DK. The company has employees across 3 continents, including EuropeNorth AmericaAfrica.

What is Orphazyme A/S's phone number?

Minus sign iconPlus sign icon
You can contact Orphazyme A/S's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Orphazyme A/S's stock symbol?

Minus sign iconPlus sign icon
Orphazyme A/S is a publicly traded company; the company's stock symbol is ORPHY.

What is Orphazyme A/S's official website and social media links?

Minus sign iconPlus sign icon
Orphazyme A/S's official website is orphazyme.com and has social profiles on LinkedIn.

What is Orphazyme A/S's SIC code NAICS code?

Minus sign iconPlus sign icon
Orphazyme A/S's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Orphazyme A/S have currently?

Minus sign iconPlus sign icon
As of December 2021, Orphazyme A/S has approximately 108 employees across 3 continents, including EuropeNorth AmericaAfrica. Key team members include Chief Commercial Officer And Us President: P. M.Head Of Global Product Strategy: A. H.Director - National Accounts: J. M.. Explore Orphazyme A/S's employee directory with LeadIQ.

What industry does Orphazyme A/S belong to?

Minus sign iconPlus sign icon
Orphazyme A/S operates in the Biotechnology Research industry.

What technology does Orphazyme A/S use?

Minus sign iconPlus sign icon
Orphazyme A/S's tech stack includes ModernizrjQuery UIIBMUbuntuWP EnginePHPYoast SEOTwitter.

What is Orphazyme A/S's email format?

Minus sign iconPlus sign icon
Orphazyme A/S's email format typically follows the pattern of . Find more Orphazyme A/S email formats with LeadIQ.

How much funding has Orphazyme A/S raised to date?

Minus sign iconPlus sign icon
As of December 2021, Orphazyme A/S has raised $109M in funding. The last funding round occurred on Feb 07, 2020 for $109M.

When was Orphazyme A/S founded?

Minus sign iconPlus sign icon
Orphazyme A/S was founded in 2009.
Orphazyme A/S

Orphazyme A/S

Biotechnology ResearchDenmark51-200 Employees

Orphazyme is a global biopharmaceutical company, headquartered in Denmark, with a rapidly growing presence in the United States. We are pioneering a new kind of treatment, applying our specialized expertise to bring innovative therapies to patients with neurodegenerative orphan diseases. With a late-stage drug pipeline, we are relentless in our commitment to advancing treatments and making a profound impact for those touched by these rare, serious diseases.

Today we are listed on Nasdaq Copenhagen (TICKER: ORPHA.CO) and Nasdaq U.S. (TICKER: ORPH), and are expanding our global presence with offices in Denmark, Switzerland, and our US headquarters in Chicago.

See our community guidelines: bit.ly/3uapRYr

Section iconCompany Overview

Headquarters
DK
Phone number
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
ORPHY
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2009
Employees
51-200

Section iconFunding & Financials

  • $109M

    Orphazyme A/S has raised a total of $109M of funding over 7 rounds. Their latest funding round was raised on Feb 07, 2020 in the amount of $109M.

Section iconFunding & Financials

  • $109M

    Orphazyme A/S has raised a total of $109M of funding over 7 rounds. Their latest funding round was raised on Feb 07, 2020 in the amount of $109M.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.